BIO-B - Bio-Rad Laboratories, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BIO-B

BIO-RAD LABORATORIES, INC.

NYSE

$368.19

▲ UP 0.85% (3.11)

KEY STATISTICS

Market Cap$10.07 B

52w High$387.10

52w Low$244.54

Dividend Yield—

Frequency—

P/E-64.83

Volume5

Shares Out.26.92M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Norman D. Schwartz

COMPENSATION 2026

Salary$1,089,877

Stock Awards$4,856,574

Incentive Plan Pay$562,088

All Other Comp.$28,327

Total$7,995,841

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 21, 1999

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

7,450

UPCOMING EARNINGS

DateOct 22, 2026

DayThursday

Rev. Est.$649.94M

OCT

THU

SPLIT RECORD

DATE	TYPE	RATIO
2002-03-08	Forward	2:1
1996-06-11	Forward	3:2
1986-06-13	Forward	3:2
1985-08-01	Forward	3:2
1980-03-19	Forward	2:1
1979-10-26	Forward	5:4
1978-11-09	Forward	5:4
1977-07-26	Forward	5:4
1976-08-26	Forward	5:4

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

BSCW

0.27%

4.1M

INSTITUTIONAL OWNERSHIP

SHARES OWNED

0.02%

HOLDERS

TOP 8 OF 11 · RANKED BY POSITION SIZE

Css LLC/Il

1.1K sh

$309.01K

Flow Traders U.S. LLC

Buckingham Strategic Wealth, LLC

Wells Fargo & Company/Mn

PRICE

$368.19 ▲ UP 48.35% (+$73.38)

OVERLAYS

—

No price history available for BIO-B over this range.

About Bio-Rad Laboratories, Inc.

https://www.bio-rad.com ↗

Bio-Rad Laboratories, Inc. develops and distributes life science research and clinical diagnostic products worldwide, serving research, biopharmaceutical, food safety, and clinical laboratories through its Life Science and Clinical Diagnostics seg...

INDUSTRY

Medical - Devices

A PRODUCT BIO-RAD LABORATORIES, INC. IS KNOWN FOR

Nuvia wPrime 2A Media

A scalable mixed-mode chromatography resin combining weak anion exchange and hydrophobic interaction, designed for efficient biomolecule purification to meet the evolving needs of biotherapeutics and research markets.

COMPETITORS

COMPETITOR

Bio-Rad Laboratories in 2025

SENTIMENT: + POSITIVE

EARNINGS · JULY 31, 2025

Bio-Rad Surges Over 17% After Smashing Q2 Earnings Expectations and Highlighting Strategic Acquisition

Bio-Rad Laboratories reported impressive second-quarter 2025 financial results, significantly beating analyst forecasts with an adjusted EPS of $2.61 versus an expected $1.75. The strong performance was coupled with the completed acquisition of Stilla Technologies, a move set to bolster its Droplet Digital PCR portfolio. This combination of strong earnings and strategic expansion led to a significant stock price rally and positive revisions to the company's full-year financial outlook.

ACQUISITION · FEBRUARY 2025 · COMPLETED

Bio-Rad Acquires Stilla Technologies to Bolster Digital PCR Portfolio and Drive Growth in Life Sciences

Bio-Rad Laboratories executed a strategic acquisition of Stilla Technologies, a developer of next-generation digital PCR systems. This move is intended to significantly enhance Bio-Rad's existing Droplet Digital PCR (ddPCR) product line, expand its offerings in applied research and clinical diagnostics, and solidify its competitive position in key growth markets.